Warrior Met Coal LLC(HCC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

HCC Warrior Met Coal LLC

Pre-Mkt 04-06 06:36:18 EDT

94.89

+2.99

+3.25%

盘前94.96

+0.07+0.07%

04:15 EDT

High95.03	Low91.60	Vol480.42K
Open91.60	D1 Closing91.90	Amplitude3.73%
Mkt Cap4.99B	Tradable Cap4.88B	Total Shares52.57M
T/O45.33M	T/O Rate0.93%	Tradable Shares51.47M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"HCC","market":"US","secType":"STK","nameCN":"Warrior Met Coal LLC","latestPrice":94.89,"timestamp":1775160000000,"preClose":91.9,"halted":0,"volume":480417,"hourTrading":{"tag":"盘前","latestPrice":94.96,"preClose":94.89,"latestTime":"04:15 EDT","volume":92,"amount":8762.379920000001,"timestamp":1775463321518,"change":0.07,"changeRate":0.000738,"amplitude":0.001159},"delay":0,"changeRate":0.03253536452665935,"floatShares":51466215,"shares":52570156,"eps":1.08,"marketStatus":"Pre-Mkt","change":2.99,"latestTime":"04-06 06:36:18 EDT","open":91.6,"high":95.025,"low":91.6,"amount":45325710.5322,"amplitude":0.037269,"askPrice":107.79,"askSize":100,"bidPrice":92.5,"bidSize":60,"shortable":3,"etf":0,"ttmEps":1.08,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1775482200000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":720248400000,"exchange":"NYSE","adjPreClose":94.89,"dividendRate":0.003372,"preHourTrading":{"tag":"盘前","latestPrice":94.96,"preClose":94.89,"latestTime":"04:15 EDT","volume":92,"amount":8762.379920000001,"timestamp":1775463321518,"change":0.07,"changeRate":0.000738,"amplitude":0.001159},"postHourTrading":{"tag":"盘后","latestPrice":94.89,"preClose":94.89,"latestTime":"19:19 EDT","volume":14636,"amount":1388846.2642,"timestamp":1775171953708,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.6356280904284508,"impliedVol":0.6313,"impliedVolPercentile":0.8675},"requestUrl":"/m/hq/s/HCC/wiki","defaultTab":"wiki","newsList":[{"id":"2625613222","title":"Do Analyst Downgrades And Weaker Coal Outlook Change The Bull Case For Warrior Met Coal (HCC)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2625613222","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2625613222?lang=en_us&edition=fundamental","pubTime":"2026-04-04 22:19","pubTimestamp":1775312388,"startTime":"0","endTime":"0","summary":"In recent days, analyst downgrades for Warrior Met Coal have cut consensus earnings estimates for 2026 and 2027, reflecting mounting concerns about weaker demand for coal amid the global shift toward cleaner energy and tightening environmental regulations.\nThis reassessment of Warrior Met Coal’s earnings outlook, coupled with a bearish industry stance from Zacks Equity Research, highlights how sector-wide decarbonization pressures may be reshaping expectations for the company’s long-term...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/2055000-choice2-main-header/1585186660639","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/2055000-choice2-main-header/1585186660639"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/materials/nyse-hcc/warrior-met-coal/news/do-analyst-downgrades-and-weaker-coal-outlook-change-the-bul","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/materials/nyse-hcc/warrior-met-coal/news/do-analyst-downgrades-and-weaker-coal-outlook-change-the-bul","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["HCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624954487","title":"Press Release: Adagene Reports Full Year 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2624954487","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624954487?lang=en_us&edition=fundamental","pubTime":"2026-04-02 05:00","pubTimestamp":1775077200,"startTime":"0","endTime":"0","summary":"In 2025, muzastotug showed 29% confirmed overall response rate  among 21 patients with MSS CRC in the 20 mg/kg dose cohorts. Median overall survival  for the 10 mg/kg cohorts was 19.4 months, with a median follow-up of 17.8 months. 4% overall discontinuation rate, no dose limiting toxicities, and no Grade 4 or 5 treatment-related adverse events  across 67 patients in all dose cohorts supports improved tolerability profile of muzastotug. Randomized Phase 2 trial enrollment ahead of plan, with potential updates in 2026 and results expected in 1H 2027; registration trial expected to begin once optimal dose regimen has been established. Cash and cash equivalents of $74.5 million as of December 31, 2025, plus proceeds raised from the ATM Offering in 2026 year-to-date, anticipated to provide cash runway into early 2028. SAN DIEGO, Calif. and SUZHOU, China, April 01, 2026  -- Adagene Inc.  , a platform-driven, clinical-stage biotechnology company transforming the discovery and development of ","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","R","BK4232","HCC","BK4006","BK4097","ORR","BK4022","ADAG","OS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624324537","title":"Press Release: Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2624324537","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624324537?lang=en_us&edition=fundamental","pubTime":"2026-04-01 04:01","pubTimestamp":1774987260,"startTime":"0","endTime":"0","summary":"Results from healthy volunteer study of next-generation STAT3 inhibitor, TTI-109, on track for Q2 2026. Topline data from Phase 2 trial of TTI-101 in hepatocellular carcinoma  are anticipated in H2 2026. Cash runway expected to be sufficient to fund operations into Q4 2026 after clinical readouts. TTI-101 was associated with a 9.4% baseline-weighted reduction in. TTI-109, is ongoing, with topline data anticipated in the second quarter. \"Further analysis of data from our Phase 2 IPF trial of TTI-101 that we announced in October revealed compelling trends. These data give us optimism for TTI-109, which has been developed to enhance TTI-101's ability to target STAT3 as a more efficient delivery vehicle with the potential to improve tolerability.\". \"At the same time, we eagerly await data from our ongoing Phase 2 REVERT LIVER CANCER trial, with a data readout expected in the second half of this year to allow for further data maturation. Interim results from this study have already shown cl","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","HCC","BK4139","LENZ","BK4007","BK4539","TVRD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623338326","title":"Coal Stocks Have (Mostly) Benefited from the Iran War. This One Is Falling Like a Rock. -- Barrons.com","url":"https://stock-news.laohu8.com/highlight/detail?id=2623338326","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623338326?lang=en_us&edition=fundamental","pubTime":"2026-03-31 03:45","pubTimestamp":1774899900,"startTime":"0","endTime":"0","summary":"While coal stocks have broadly advanced since the start of the U.S. and Israel-led war with Iran, Peabody Energy shares sank Monday after the coal pure play announced that first-quarter shipment volumes from a mine will be lower than previously expected.The leading global supplier of coal reported in regulatory filings Monday that \"based on recent events\" around mine commissioning challenges, it forecasts shipments of 250,00 tons from its Centurion mine in Australia compared with prior forecasts of around 700,000 tons.Peabody Energy kept its full-year 2026 shipment targets for metallurgical coal, a critical component in blast-furnace steel production, unchanged at 10.3 million tons to 11.3 million tons.The stock, which had risen 25% since the start of the war entering into Monday, sank 11% to $35.17. The S&P 500 fell 0.7% and the Dow Jones Industrial Average was down 0.1% on Monday.Fellow coal stocks Core Natural Resources, Alpha Metallurgical Resources, and Warrior Met Coal have also ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","BK4086","BTU","CNR","BK4588","HCC","VDE","BK4585","AMR","BK4156"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623345052","title":"Press Release: Harbour BioMed Reports Full Year 2025 Financial Results: Sustained Global Collaboration Underpins Long-Term Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2623345052","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623345052?lang=en_us&edition=fundamental","pubTime":"2026-03-30 21:54","pubTimestamp":1774878840,"startTime":"0","endTime":"0","summary":"CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 30, 2026 /PRNewswire/ -- Harbour BioMed , a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other areas, today announced its financial results for the year ended December 31, 2025.Dr. Jingsong Wang, Founder, Chairman, and CEO of Harbour BioMed, commented: \"2025 marked a pivotal year for Harbour BioMed as we entered the third phase of our strategic evolution, with a clear roadmap toward our 2028 vision of becoming a global leading platform-based biopharmaceutical group.The Company's strategy is powered by three integrated growth engines. These include building a global leading AI-driven antibody discovery 'new infrastructure' through Nona Biosciences, expanding global partnerships through platform-based collaborations with multinational pharmaceutical companies, and unlocking the global value of its mid- to late-stage pipeline in immunology,","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","02142","BK4232","NEN","BK4213","BK4113","HCC","R","TSLP","LU0266512127.USD","BK4097","BK4233","BK1583","BK1161","BK4205","BK1574","CRC","LU0456854461.SGD","BK4022","OS","MSS","BK4590","ORR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623141593","title":"Can-Fite’s Partner Vetbiolix Completes Enrollment in Phase 2 Osteoarthritis Study in Dogs Treated with Piclidenoson; Data Expected in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2623141593","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2623141593?lang=en_us&edition=fundamental","pubTime":"2026-03-30 19:20","pubTimestamp":1774869600,"startTime":"0","endTime":"0","summary":"Can-Fite Signed a Deal Worth up to $325M with the Veterinary Company Vetbiolix Ramat Gan, Israel, March  30, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biot","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/30/3264512/0/en/Can-Fite-s-Partner-Vetbiolix-Completes-Enrollment-in-Phase-2-Osteoarthritis-Study-in-Dogs-Treated-with-Piclidenoson-Data-Expected-in-Q3-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCC","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622887653","title":"Warrior Met Coal Is Maintained at Buy by UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2622887653","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622887653?lang=en_us&edition=fundamental","pubTime":"2026-03-27 23:49","pubTimestamp":1774626540,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/HCC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 27, 2026 11:49 ET (15:49 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCC","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622822561","title":"Warrior Met Coal price target raised to $105 from $101 at UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2622822561","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622822561?lang=en_us&edition=fundamental","pubTime":"2026-03-27 21:15","pubTimestamp":1774617312,"startTime":"0","endTime":"0","summary":"UBS analyst George Eadie raised the firm’s price target on Warrior Met Coal (HCC) to $105 from $101 and keeps a Buy rating on the shares. Published...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/warrior-met-coal-price-target-raised-to-105-from-101-at-ubs-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/warrior-met-coal-price-target-raised-to-105-from-101-at-ubs-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MMAT","UBS","IE0034235071.USD","BK4118","LU1863844665.USD","BK4141","BK4588","BK4006","HCC","BK4585","LU1863844749.USD","LU3187612489.SGD","BK4534","LU1829250122.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622811748","title":"Press Release: Akeso Reports Full-Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2622811748","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622811748?lang=en_us&edition=fundamental","pubTime":"2026-03-27 11:54","pubTimestamp":1774583640,"startTime":"0","endTime":"0","summary":"HONG KONG, March 26, 2026 /PRNewswire/ -- Akeso, Inc.   announced its 2025 annual results, highlighting a year of comprehensive, strategic leaps across all facets of its business.In 2025, Akeso achieved record commercial sales revenue of RMB3,033.1 million, a 51.48% year-on-year increase. All approved products and indications are now included in China's National Reimbursement Drug List . The strong commercial growth in 2025 was fueled by strong clinical validation and widespread adoption by both healthcare professionals and patients.By the end of 2025, several high-impact indications were added to the latest NRDL, including:. -- Cadonilimab: 1L gastric cancer and 1L cervical cancer. With stable pricing for core first-line  indications and improved hospital access, Akeso's commercial platform is positioned for a transformative 2026.As the world's first and only approved PD-1/VEGF bispecific antibody, ivonescimab solidified its global leadership in 2025 by iterating upon existing Standar","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0417516571.SGD","AIYY","BK4551","BK4006","LU2778985437.USD","LU0348784397.USD","09926","AGIX","BK4023","LU0561508036.HKD","LU2399975544.HKD","LU2476274720.SGD","BK4585","LU1794554557.SGD","LU1961090484.USD","LU1720050803.USD","BK4213","HCC","LU0348766576.USD","AIPO","LU0348735423.USD","LU0348783233.USD","BK4528","LU0540923850.HKD","LU0634319403.HKD","IE00BPRC5H50.USD","BK4587","AI","LU0348827113.USD","LU2488822045.USD","IE00B543WZ88.USD","CHAT","BK1161","LU0348767384.USD","BK1574","LU0417516738.SGD","LU0348825331.USD","LU0417516902.SGD","BK4543","SOC","BK4588","IE00B5MMRT66.SGD","LU2476274308.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622247863","title":"Press Release: CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0","url":"https://stock-news.laohu8.com/highlight/detail?id=2622247863","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622247863?lang=en_us&edition=fundamental","pubTime":"2026-03-26 21:32","pubTimestamp":1774531920,"startTime":"0","endTime":"0","summary":"-- The global, multicenter Phase I/II clinical trial of CS2009. Australia and China, and the Phase II IND application has been approved. in the US. CS2009 demonstrates an excellent safety profile with a >=Grade. 3 TRAE rate of 23%, along with broad-spectrum anti-tumor activity.Notably, monotherapy data in lung cancer are encouraging: in first-line. NSCLC patients with PD-L1 TPS >=50%, the ORR reached 90% with a DCR of. 100%, while the ORR was 25% in IO-pretreated NSCLC .Furthermore, significant benefits were observed in patients with heavily. pre-treated \"cold tumors,\" achieving an ORR of 40% in non-clear cell. renal cell carcinoma  and 33.3% in soft tissue sarcoma .-- The global Phase Ib multicenter trial of CS5001  is being. advanced rapidly and efficiently in Australia and China, with its R&D. progress ranking among the top two globally. In combination with R-CHOP. rate exceeds 90%, and the ORR reaches 100%. Additionally, the combination. complementing its successful NRDL renewal at","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4213","BK1574","BK4006","LU2413666699.HKD","BK4218","BK4107","PD","LU1169590202.USD","HCC","PROC","02616","LU1093756325.SGD","IE00BYQQ9H92.USD","BK4007","LU2413666426.HKD","CC","R","BK4533","LU2487616109.SGD","CRC","BK4121","LU1169589451.USD","BK4232","LU0456854461.SGD","LU2211817866.USD","IE00BFXG0V08.USD","L","BK1161","BK4098","LU0266512127.USD","BK4548","BK4156","LU1093756168.USD","BK4585","BK4181","LU0053666078.USD","ORR","PK","BK4567","MTD","BK4588","LU0210528500.USD","BK4022","LU1721428933.USD","LU0347712357.USD","BK4023","IE00B5TLWC47.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622863932","title":"Press Release: Can-Fite Reports 2025 Financial Results and Ongoing Clinical Progress Highlighting Positive Data in Phase 2a Pancreatic cancer and 9 Years Cancer-Free Survival in Liver Cancer Patient","url":"https://stock-news.laohu8.com/highlight/detail?id=2622863932","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622863932?lang=en_us&edition=fundamental","pubTime":"2026-03-26 21:27","pubTimestamp":1774531620,"startTime":"0","endTime":"0","summary":"RAMAT GAN, Israel, March 26, 2026  -- Can-Fite BioPharma Ltd.  , a biotechnology company developing a pipeline of proprietary small molecule drugs targeting oncological and inflammatory diseases, today announced clinical updates and financial results for the year ended December 31, 2025 and early 2026.Phase 2a study in pancreatic cancer met its primary endpoint of safety in heavily pretreated patients. The study continues to follow patients for overall survival, with data maturing over time; currently more than 30% of patients are alive at last data cut-off.Motti Farbstein Can-Fite's CEO&CFO stated: \"The past months have marked a period of significant progress for Can-Fite, highlighted by encouraging clinical signals across multiple indications and continued expansion of our intellectual property portfolio. Notably, clinical observations in adva","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4097","LU2065732104.USD","CANF","PRGS","HCC","BK4139","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621770748","title":"Press Release: Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2621770748","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621770748?lang=en_us&edition=fundamental","pubTime":"2026-03-23 19:30","pubTimestamp":1774265400,"startTime":"0","endTime":"0","summary":"Strong financial position with cash, cash equivalents and marketable securities of $91.5M as of December 2025. $2.25B Moderna global settlement for infringement of lipid nanoparticle  delivery technology represents significant outcome for Arbutus and Genevant. Two additional patients from Phase 2a clinical trials of imdusiran achieve functional cure. Milestone payment received under Alnylam LNP license for product candidate to treat hepatocellular carcinoma . WARMINSTER, Pa., March 23, 2026  -- Arbutus Biopharma Corporation  , a clinical-stage biopharmaceutical company focused on infectious disease, today reported fourth quarter and year end 2025 financial results and provided a corporate update.\"We delivered another strong quarter, maintaining a disciplined approach to capital allocation and a continued focus on maximizing our cash runway,\" said Lindsay Androski, President and CEO of Arbutus. \"I am thrilled to announce that two additional patients from our Phase 2a trials of imdusiran","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"8603dabb40994e59ac78c04c930c0d49","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCC","BK4006","ABUS","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620731211","title":"HCC Wins Rs 1,662 Crore JV Contract for Mumbai Goregaon-Mulund Link Road Phase IV","url":"https://stock-news.laohu8.com/highlight/detail?id=2620731211","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620731211?lang=en_us&edition=fundamental","pubTime":"2026-03-19 14:54","pubTimestamp":1773903298,"startTime":"0","endTime":"0","summary":"Hindustan Construction Co. Ltd. ( ($IN:HCC) ) has shared an announcement. Hindustan Construction Company Ltd. has secured an infrastructure contrac...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/hcc-wins-rs-1662-crore-jv-contract-for-mumbai-goregaon-mulund-link-road-phase-iv?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/hcc-wins-rs-1662-crore-jv-contract-for-mumbai-goregaon-mulund-link-road-phase-iv?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["HCC","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620257016","title":"Warrior Met Coal Is Maintained at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2620257016","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620257016?lang=en_us&edition=fundamental","pubTime":"2026-03-18 23:16","pubTimestamp":1773846960,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/HCC/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  March 18, 2026 11:16 ET (15:16 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4006","HCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620040191","title":"Adagene’s Muzastotug (ADG126) to be Highlighted in Two Presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting in San Diego, CA","url":"https://stock-news.laohu8.com/highlight/detail?id=2620040191","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620040191?lang=en_us&edition=fundamental","pubTime":"2026-03-18 04:35","pubTimestamp":1773779700,"startTime":"0","endTime":"0","summary":"SAN DIEGO and SUZHOU, China, March  17, 2026 (GLOBE NEWSWIRE) -- Adagene Inc. (“Adagene or the Company”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based th","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/17/3257692/0/en/Adagene-s-Muzastotug-ADG126-to-be-Highlighted-in-Two-Presentations-at-the-2026-American-Association-for-Cancer-Research-AACR-Annual-Meeting-in-San-Diego-CA.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRC","LU0456854461.SGD","BK4139","BK4006","ADAG","BK4113","AFG","BK4213","HCC","MSS","BK4117","CA","BK4107","LU0266512127.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620424079","title":"Can-Fite Expands Namodenoson anti-Obesity Franchise with Israeli Patent Allowance","url":"https://stock-news.laohu8.com/highlight/detail?id=2620424079","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620424079?lang=en_us&edition=fundamental","pubTime":"2026-03-17 19:47","pubTimestamp":1773748020,"startTime":"0","endTime":"0","summary":"Strengthens global IP and supports strategic positioning in the rapidly growing metabolic therapeutics market Ramat Gan, Israel, March  17, 2026 (GLOBE NEWSWIRE) --  Can-Fite BioPharma Ltd. (NYSE Amer","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/17/3257054/0/en/Can-Fite-Expands-Namodenoson-anti-Obesity-Franchise-with-Israeli-Patent-Allowance.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCC","BK4006","BK4159","CAGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618325991","title":"UBS Adjusts Price Target on Warrior Met Coal to $101 From $100, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2618325991","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618325991?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:57","pubTimestamp":1773320238,"startTime":"0","endTime":"0","summary":"Warrior Met Coal (HCC) has an average rating of overweight and mean price target of $106.17, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from m","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["HCC","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618349241","title":"Warrior Met Coal Inc : UBS Raises Target Price to $101 From $100","url":"https://stock-news.laohu8.com/highlight/detail?id=2618349241","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618349241?lang=en_us&edition=fundamental","pubTime":"2026-03-12 20:28","pubTimestamp":1773318497,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260312:nAZN4SKVW3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HCC","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618582759","title":"Warrior Met Coal Inc. announced its annual stockholders meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2618582759","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618582759?lang=en_us&edition=fundamental","pubTime":"2026-03-10 20:49","pubTimestamp":1773146963,"startTime":"0","endTime":"0","summary":"Warrior Met Coal will hold its annual meeting on April 20, 2026 via virtual attendance only. Shareholders will vote to elect six director nominees to the board. They will also vote on adopting the 2026 Equity Incentive Plan and on a non-binding advisory resolution on named executive officer compensation. In addition, shareholders will vote to ratify the appointment of Ernst and Young as independent registered public accounting firm for the year ending December 31, 2026.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Warrior Met Coal Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on Mar","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nNDL8z1m8d:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCC","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617555401","title":"Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds","url":"https://stock-news.laohu8.com/highlight/detail?id=2617555401","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2617555401?lang=en_us&edition=fundamental","pubTime":"2026-03-04 23:25","pubTimestamp":1772637900,"startTime":"0","endTime":"0","summary":"RAMAT GAN, Israel, March  04, 2026  (GLOBE NEWSWIRE) --  Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) (“Can-Fite” or the “Company”), a biotechnology company advancing a pipeline of propr","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/04/3249502/0/en/Can-Fite-Announces-Exercise-of-Warrants-for-Approximately-4-0-Million-in-Gross-Proceeds.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCC","BK4006"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.warriormetcoal.com","stockEarnings":[{"period":"1week","weight":-0.0076},{"period":"1month","weight":0.158},{"period":"3month","weight":0.0596},{"period":"6month","weight":0.4787},{"period":"1year","weight":1.0323},{"period":"ytd","weight":0.0762}],"compareEarnings":[{"period":"1week","weight":0.0166},{"period":"1month","weight":-0.036},{"period":"3month","weight":-0.04},{"period":"6month","weight":-0.02},{"period":"1year","weight":0.1617},{"period":"ytd","weight":-0.0383}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Warrior Met Coal, Inc. produces and exports non-thermal metallurgical coal for the steel industry. It operates two underground mines located in Alabama. The company sells its metallurgical coal to a customer base of blast furnace steel producers located primarily in Europe, South America, and Asia. It also sells natural gas, which is extracted as a byproduct from coal production. Warrior Met Coal, Inc. was incorporated in 2015 and is headquartered in Brookwood, Alabama.","yearOnYearQuotes":[{"month":1,"riseRate":0.777778,"avgChangeRate":0.047428},{"month":2,"riseRate":0.444444,"avgChangeRate":-0.016436},{"month":3,"riseRate":0.444444,"avgChangeRate":-0.028693},{"month":4,"riseRate":0.555556,"avgChangeRate":-0.004067},{"month":5,"riseRate":0.444444,"avgChangeRate":0.012171},{"month":6,"riseRate":0.666667,"avgChangeRate":0.009594},{"month":7,"riseRate":0.777778,"avgChangeRate":0.07587},{"month":8,"riseRate":0.444444,"avgChangeRate":0.020482},{"month":9,"riseRate":0.666667,"avgChangeRate":0.034825},{"month":10,"riseRate":0.555556,"avgChangeRate":0.03995},{"month":11,"riseRate":0.666667,"avgChangeRate":0.081356},{"month":12,"riseRate":0.777778,"avgChangeRate":0.058477}],"exchange":"NYSE","name":"Warrior Met Coal LLC","nameEN":"Warrior Met Coal LLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Warrior Met Coal LLC(HCC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Warrior Met Coal LLC(HCC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Warrior Met Coal LLC,HCC,Warrior Met Coal LLC股票,Warrior Met Coal LLC股票老虎,Warrior Met Coal LLC股票老虎国际,Warrior Met Coal LLC行情,Warrior Met Coal LLC股票行情,Warrior Met Coal LLC股价,Warrior Met Coal LLC股市,Warrior Met Coal LLC股票价格,Warrior Met Coal LLC股票交易,Warrior Met Coal LLC股票购买,Warrior Met Coal LLC股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Warrior Met Coal LLC(HCC),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Warrior Met Coal LLC(HCC) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}